128 related articles for article (PubMed ID: 18845652)
1. Anti-GM1 antibodies are not associated with cerebral atrophy in patients with multiple sclerosis.
Valentino P; Labate A; Nisticò R; Pirritano D; Cerasa A; Liguori M; Bastone L; Crescibene L; Quattrone A
Mult Scler; 2009 Jan; 15(1):114-5. PubMed ID: 18845652
[TBL] [Abstract][Full Text] [Related]
2. Gray matter atrophy in multiple sclerosis: a longitudinal study.
Fisher E; Lee JC; Nakamura K; Rudick RA
Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
[TBL] [Abstract][Full Text] [Related]
3. Serum IgG and IgM ganglioside GM1 antibodies in patients with multiple sclerosis.
Zaprianova E; Majtényi K; Deleva D; Mikova O; Filchev A; Sultanov B; Kolyovska V; Sultanov E; Christova L; Kmetska X; Georgiev D
Ideggyogy Sz; 2004 Mar; 57(3-4):94-9. PubMed ID: 15133910
[TBL] [Abstract][Full Text] [Related]
4. Gender-related differences in MS: a study of conventional and nonconventional MRI measures.
Antulov R; Weinstock-Guttman B; Cox JL; Hussein S; Durfee J; Caiola C; Dwyer MG; Bergsland N; Abdelrahman N; Stosic M; Hojnacki D; Munschauer FE; Miletic D; Zivadinov R
Mult Scler; 2009 Mar; 15(3):345-54. PubMed ID: 19028830
[TBL] [Abstract][Full Text] [Related]
5. The topographical distribution of tissue injury in benign MS: a 3T multiparametric MRI study.
Ceccarelli A; Rocca MA; Pagani E; Ghezzi A; Capra R; Falini A; Scotti G; Comi G; Filippi M
Neuroimage; 2008 Feb; 39(4):1499-509. PubMed ID: 18155611
[TBL] [Abstract][Full Text] [Related]
6. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis.
Battaglini M; Giorgio A; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
J Neurol Sci; 2009 Jul; 282(1-2):55-60. PubMed ID: 19286193
[TBL] [Abstract][Full Text] [Related]
7. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.
Tedeschi G; Dinacci D; Comerci M; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Patti F; Morra VB; Servillo G; Orefice G; Paciello M; Prinster A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Brunetti A; Salemi G; D'Amelio M; Simone I; Salvatore M; Bonavita V; Alfano B
Mult Scler; 2009 Feb; 15(2):204-11. PubMed ID: 18987104
[TBL] [Abstract][Full Text] [Related]
8. Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis.
Schwarz M; Spector L; Gortler M; Weisshaus O; Glass-Marmor L; Karni A; Dotan N; Miller A
J Neurol Sci; 2006 May; 244(1-2):59-68. PubMed ID: 16480743
[TBL] [Abstract][Full Text] [Related]
9. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
[TBL] [Abstract][Full Text] [Related]
10. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
[TBL] [Abstract][Full Text] [Related]
11. Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis.
Khalil M; Enzinger C; Langkammer C; Tscherner M; Wallner-Blazek M; Jehna M; Ropele S; Fuchs S; Fazekas F
Mult Scler; 2009 Sep; 15(9):1048-54. PubMed ID: 19556316
[TBL] [Abstract][Full Text] [Related]
12. Associations between cervical cord gray matter damage and disability in patients with multiple sclerosis.
Agosta F; Pagani E; Caputo D; Filippi M
Arch Neurol; 2007 Sep; 64(9):1302-5. PubMed ID: 17846269
[TBL] [Abstract][Full Text] [Related]
13. Contribution of white matter lesions to gray matter atrophy in multiple sclerosis: evidence from voxel-based analysis of T1 lesions in the visual pathway.
Sepulcre J; Goñi J; Masdeu JC; Bejarano B; Vélez de Mendizábal N; Toledo JB; Villoslada P
Arch Neurol; 2009 Feb; 66(2):173-9. PubMed ID: 19204153
[TBL] [Abstract][Full Text] [Related]
14. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis.
Benedetti B; Rovaris M; Rocca MA; Caputo D; Zaffaroni M; Capra R; Bertolotto A; Martinelli V; Comi G; Filippi M
Mult Scler; 2009 Jul; 15(7):789-94. PubMed ID: 19465450
[TBL] [Abstract][Full Text] [Related]
15. (1)H-MRSI evidence for cortical gray matter pathology that is independent of cerebral white matter lesion load in patients with secondary progressive multiple sclerosis.
Caramanos Z; DiMaio S; Narayanan S; Lapierre Y; Arnold DL
J Neurol Sci; 2009 Jul; 282(1-2):72-9. PubMed ID: 19232641
[TBL] [Abstract][Full Text] [Related]
16. Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study.
Ramasamy DP; Benedict RH; Cox JL; Fritz D; Abdelrahman N; Hussein S; Minagar A; Dwyer MG; Zivadinov R
J Neurol Sci; 2009 Jul; 282(1-2):47-54. PubMed ID: 19201003
[TBL] [Abstract][Full Text] [Related]
17. Evolution of self-reactive IgG antibody repertoires in patients with relapsing-remitting multiple sclerosis.
Lionel A; de Seze J; Didier L; Sandrine FN; Sylvain D; Patrick V; Lionel P
Immunol Lett; 2005 Feb; 97(1):55-62. PubMed ID: 15626476
[TBL] [Abstract][Full Text] [Related]
18. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
[TBL] [Abstract][Full Text] [Related]
19. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing-remitting multiple sclerosis.
Liguori M; Fera F; Patitucci A; Manna I; Condino F; Valentino P; Telarico P; Cerasa A; Gioia MC; di Palma G; Quattrone A
Brain Res; 2009 Feb; 1256():123-8. PubMed ID: 19071096
[TBL] [Abstract][Full Text] [Related]
20. Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis.
Zivadinov R; Weinstock-Guttman B; Zorzon M; Uxa L; Serafin M; Bosco A; Bratina A; Maggiore C; Grop A; Tommasi MA; Srinivasaraghavan B; Ramanathan M
J Neuroimmunol; 2009 Apr; 209(1-2):123-30. PubMed ID: 19232441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
